Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial by Choueiri, Toni K, Dr, Escudier, Bernard, MD, Powles, Thomas, Prof, Tannir, Nizar M, Prof, Mainwaring, Paul N, MD, Rini, Brian I, Prof, Hammers, Hans J, MD, Donskov, Frede, MD, Roth, Bruce J, Prof, Peltola, Katriina, MD, Lee, Jae Lyun, Prof, Heng, Daniel Y C, MD, Schmidinger, Manuela, Prof, Agarwal, Neeraj, MD, Sternberg, Cora N, Prof, McDermott, David F, MD, Aftab, Dana T, PhD, Hessel, Colin, MS, Scheffold, Christian, MD, Schwab, Gisela, MD, Hutson, Thomas E, Prof, Pal, Sumanta, MD, Motzer, Robert J, Prof

Get full text